A new real-world study suggests that semaglutide—sold under brand names such as Ozempic, Wegovy, and Rybelsus—may provide an unexpected benefit beyond blood sugar control and weight loss. Researchers analyzed health records from nearly 60,000 adults with type 2 diabetes and found that those taking semaglutide experienced approximately 15% fewer bone fractures compared with people using other common weight-loss medications.
What makes the finding particularly notable is that semaglutide users lost more weight, a factor that can sometimes be associated with reduced bone density. The results suggest that semaglutide may help protect bone health while supporting weight management. Further research is needed, but the study offers encouraging news for people managing type 2 diabetes and obesity.
Read more at ScienceDaily